Amaran Biotech, a leading Contract Development and Manufacturing Organization (CDMO), was awarded the prestigious “Best CDMO in Automated Aseptic Filling” at the Taiwan Biopharma Excellence Awards 2025 on March 26. The ceremony, held at the Hilton Taipei Sinban, recognized Amaran Biotech’s pivotal role in advancing automated aseptic filling technologies in the biopharmaceutical sector.
Organized by IMAPAC, a renowned international consulting firm, the Taiwan Biopharma Excellence Awards honor organizations and technologies that drive innovation and excellence in biomanufacturing. The event, which coincided with IMAPAC’s 12th Biologics World Taiwan 2025 and the 4th Stem Cells & Regenerative Medicine Asia 2025 conference, brought together nearly 300 industry leaders from Taiwan’s top biopharmaceutical and vaccine manufacturing companies.
Amaran Biotech’s achievement stems from its introduction of Taiwan’s first fully automated aseptic filling line in 2022. Using the Cytiva (Vanrx) SA25 robotic aseptic filling system, the company minimized human intervention in the filling process, enhancing the safety and efficiency of drug manufacturing. This advanced technology enables the high-quality, low-waste filling of high-value biologics, such as protein therapeutics, antibody drugs, and nanoparticle-based drugs. The system supports a variety of container types, including vials, pre-filled syringes, and cartridges, offering a remarkable filling accuracy of 99.99%.
In her acceptance speech, Dr. Tessie Che, Chairperson and General Manager of Amaran Biotech, expressed gratitude for the recognition. “This award is a testament to the hard work and dedication of our entire team,” she said. “When we decided to build our automated aseptic filling line in 2020, the Covid-19 pandemic presented unforeseen challenges. With international travel restrictions preventing engineers from traveling to Taiwan for on-site installation, our team worked tirelessly through remote collaboration with the equipment manufacturer. We overcame these obstacles to meet the stringent regulatory standards of the FDA, EMA, ICH, PIC/S, and ISPE. Looking ahead, Amaran Biotech remains committed to utilizing high-tech innovations, including AI integration, to provide customized CDMO services and cement our position as a global leader in pharmaceutical manufacturing.”
About Amaran Biotech
Amaran Biotech is a Contract Development and Manufacturing Organization (CDMO) that specializes in drug process development, analytical services, and cGMP manufacturing of high-value biopharmaceuticals. The company’s cutting-edge manufacturing facility, located in the Hsinchu Biomedical Science Park, has held PIC/S GMP certification from the Taiwan Food and Drug Administration (TFDA) since 2017. It is also regularly audited and qualified by regulatory agencies and third-party auditors from the USA and the EU. In 2020, Amaran Biotech became a subsidiary of OBI Pharma. In 2024, its Building C received the Green Building Certification from Taiwan’s Ministry of the Interior. Dr. Tessie Che, a seasoned expert in the global pharmaceutical and biotech industries, has successfully led the registration and commercialization of the antibiotic drug DIFICID® (Fidaxomicin) in the U.S., Canada, and Europe.
You Might Be Interested In:
